SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0000950170-23-015250
Filing Date
2023-04-27
Accepted
2023-04-27 16:02:46
Documents
53
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 6-K asnd-20230331.htm   iXBRL 6-K 2062037
2 GRAPHIC img147634149_0.jpg GRAPHIC 24005
3 GRAPHIC img147634149_1.jpg GRAPHIC 97935
4 GRAPHIC img147634149_2.jpg GRAPHIC 44326
  Complete submission text file 0000950170-23-015250.txt   7680557

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT asnd-20230331.xsd EX-101.SCH 47661
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT asnd-20230331_def.xml EX-101.DEF 176635
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT asnd-20230331_pre.xml EX-101.PRE 266371
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT asnd-20230331_cal.xml EX-101.CAL 50472
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT asnd-20230331_lab.xml EX-101.LAB 356980
47 EXTRACTED XBRL INSTANCE DOCUMENT asnd-20230331_htm.xml XML 1577209
Mailing Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900
Business Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900 45 70 22 22 44
Ascendis Pharma A/S (Filer) CIK: 0001612042 (see all company filings)

IRS No.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-36815 | Film No.: 23856667
SIC: 2834 Pharmaceutical Preparations